Viewing Study NCT00987818


Ignite Creation Date: 2025-12-25 @ 4:30 AM
Ignite Modification Date: 2026-02-22 @ 7:29 PM
Study NCT ID: NCT00987818
Status: WITHDRAWN
Last Update Posted: 2015-09-02
First Post: 2009-09-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Procalcitonin Guided Versus Conventional Antibiotic Therapy in Patients With Sepsis in the ICU
Sponsor: Rijnstate Hospital
Organization:

Study Overview

Official Title: Reduction of Antibiotic Use in the ICU: Procalcitonin Guided Versus Conventional Antibiotic Therapy in Patients With Sepsis in the ICU
Status: WITHDRAWN
Status Verified Date: 2012-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: No MEC approval
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The adequacy of early empiric antimicrobial therapy is an important factor in determining the outcome in patients with severe sepsis. The duration of adequate antibiotic therapy in these patients however is less clear. Duration of antibiotic therapy in patients with sepsis in the ICU based on inflammatory markers has not been extensively studied.

Procalcitonin (PCT) is an acute phase protein that has prognostic value in critically ill patients and can be used to monitor disease activity in sepsis and systemic inflammation. This study will examine the effect of PCT guided antibiotic therapy compared with conventional antibiotic therapy on treatment duration in patients with sepsis admitted to the ICU.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: